THE HEALTH SERVICE Executive is missing out on potential savings because of a delay in introducing reference pricing of prescription drugs under the medical card scheme.

The Medical Independent has learned that if reference pricing had been introduced in 2010 for just two of the most widely prescribed drugs under the General Medical Services scheme, the HSE would have saved €19.07 million.

June Shannon reports that this figure would be saved on statins and proton pump inhibitors alone. The two drugs are commonly prescribed to control cholesterol and treat stomach problems.

Reference pricing refers to a type of drugs payment system which groups together pharmaceuticals with the same active ingredient. It would see pharmacists paid one price for the products in each group, regardless of whether it was a generic or a proprietary drug. The system is commonly used across Europe.

For more details, read June Shannon’s article in the Medical Independent>

Making a difference

A mix of advertising and supporting contributions helps keep paywalls away from valuable information like this article. Over 5,000 readers like you have already stepped up and support us with a monthly payment or a once-off donation.

For the price of one cup of coffee each week you can make sure we can keep reliable, meaningful news open to everyone regardless of their ability to pay.

Support us Learn More

HSE losing money over delay in reference pricing

For more details, read June Shannon’s article in the Medical Independent>

Making a difference

A mix of advertising and supporting contributions helps keep paywalls away from valuable information like this article. Over 5,000 readers like you have already stepped up and support us with a monthly payment or a once-off donation.